Drug-induced Fatty Liver Disease: Pathogenesis and Treatment

Tea Omanovic Kolaric; Vjera Nincevic; Lucija Kuna; Kristina Duspara; Kristina Bojanic; Sonja Vukadin; Nikola Raguz-Lucic; George Y Wu; Martina Smolic

doi:10.14218/JCTH.2020.00091

Drug-induced Fatty Liver Disease: Pathogenesis and Treatment

J Clin Transl Hepatol. 2021 Oct 28;9(5):731-737. doi: 10.14218/JCTH.2020.00091. Epub 2021 Sep 14.

Authors

Tea Omanovic Kolaric^{1

2}, Vjera Nincevic^{1

2}, Lucija Kuna^{1

2}, Kristina Duspara¹, Kristina Bojanic^{1

2

3}, Sonja Vukadin^{1

2}, Nikola Raguz-Lucic^{1

2}, George Y Wu⁴, Martina Smolic^{1

2}

Affiliations

¹ University of Osijek, Faculty of Medicine, Osijek, Croatia.
² University of Osijek, Faculty of Dental Medicine and Health, Osijek, Croatia.
³ Health Center Osijek, Osijek, Croatia.
⁴ Department of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Farmington, CT, USA.

Abstract

Metabolic dysfunction-associated fatty liver disease (commonly known as MAFLD) impacts global health in epidemic proportions, and the resulting morbidity, mortality and economic burden is enormous. While much attention has been given to metabolic syndrome and obesity as offending factors, a growing incidence of polypharmacy, especially in the elderly, has greatly increased the risk of drug-induced liver injury (DILI) in general, and drug-induced fatty liver disease (DIFLD) in particular. This review focuses on the contribution of DIFLD to DILI in terms of epidemiology, pathophysiology, the most common drugs associated with DIFLD, and treatment strategies.

Keywords: Drug-induced liver injury; Free fatty acids; Metabolic dysfunction-associated fatty liver disease; Pharmacogenetics; Reactive oxygen species.

Publication types

Review